The University of Maryland Marlene and Stewart Greenebaum Cancer Center
(UMGCC) has a long and rich history of cancer research, patient care and medical
education throughout the state of Maryland and the Mid-Atlantic region. Located on
the medical campus of the University of Maryland at Baltimore, the Center is part
of both the University of Maryland Medical Center and the University of Maryland
School of Medicine. All of the center's researchers and physicians are on the
faculty of the medical school and other professional schools at the University of
Maryland, Baltimore. The center was named in honor of real estate developer and
businessman Stewart Greenebaum and his wife, Marlene, a breast cancer survivor.
The mission of the UMGCC is to undertake innovative basic and clinical
research that will impact the understanding and treatment of cancer around the
world and to provide state–of–the–art clinical care to cancer patients in Maryland
and beyond. We conduct an interactive, multidisciplinary research program focusing
on the rapid transfer of knowledge from the laboratory to the clinic. We have
developed a national and international reputation as an institution with expertise
in laboratory and clinical research providing new approaches to cancer treatment.
Research performed at the UMGCC has had a significant impact on cancer care worldwide,
particularly the pioneering work of Dr. Angela Brodie for the development of aromatase
inhibitors for the treatment of breast cancer.
Our goal is to take advantage of discoveries in basic cancer biology in conjunction
with clinical research to: develop and apply innovative cancer treatment and prevention
strategies; describe the molecular mechanisms underlying specific clinical phenotypes
and behaviors; and apply these discoveries and strategies to the Maryland community and
beyond, with a specific focus on cancer disparities.
 |
